Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus TACE in hepatocellular carcinoma
ChiCTR-OIN-17010698Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of endostar in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Overall survival. Started Mar 2017; status: recruiting.
02
Drugs
endostar
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OIN-17010698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17010698.